	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	1,313	1,626	1,638	1,644	1,674	1,635	1,874	2,779	2,363	1,542	1,665	1,520	1,682	-	2	7
Cost of Operating Revenue	1,050	1,312	1,329	1,323	1,347	1,328	1,575	2,434	2,058	1,346	1,426	1,377	1,429	1	0	4
Gross Profit	263	314	310	321	327	308	299	345	305	196	239	144	253	-1	2	4
Gross Margin	20.0	19.3	18.9	19.5	19.5	18.8	15.9	12.4	12.9	12.7	14.3	9.4	15.0	-	82.9	48.6
Total Operating Expenses	1,136	1,412	1,434	1,453	1,493	1,473	1,702	2,578	2,204	1,492	1,564	1,525	1,589	1	9	95
Operating Profit	177	214	205	190	182	162	172	201	159	50	102	-5	92	-1	-7	-87
Operating Margin	13.5	13.2	12.5	11.6	10.8	9.9	9.2	7.2	6.7	3.2	6.1	-0.3	5.5	-	-337.1	-1,171.8
Financing Income/(Expense) - Net	-103	-99	-126	-110	-118	-111	-110	-142	-123	-109	-77	-78	-75	1	-81	-36
Profit before Taxes	85	115	78	85	64	67	63	59	37	-85	34	-42	18	1	-88	-114
Income Taxes	12	29	16	18	10	12	10	11	6	-12	9	-18	13	0	-31	-40
Profit after Tax	73	86	62	66	54	55	52	48	32	-73	25	-24	5	-114	-293	-538
PAT Margin	5.6	5.3	3.8	4.0	3.2	3.4	2.8	1.7	1.3	-4.8	1.5	-1.6	0.3	-	-14,564.4	-7,228.4
EPS - Basic - ex Extraordinary Items	3.26	3.82	2.77	2.95	2.42	2.47	2.33	2.12	1.42	-3.27	1.12	-1.08	0.22	0.03	-2.62	-4.02
EPS - Diluted - ex Extraordinary Items	3.26	3.82	2.77	2.95	2.42	2.47	2.33	2.12	1.42	-3.27	1.12	-1.08	0.22	0.03	-2.62	-4.02
EBIT	177	214	205	190	182	162	172	201	159	50	102	-5	92	-1	-7	-87
EBITDA	237	290	289	267	239	224	236	264	220	110	159	54	153	62	-6	-87
EBITDA Margin	18.1	17.8	17.6	16.2	14.3	13.7	12.6	9.5	9.3	7.2	9.5	3.5	9.1	-	-320.0	-1,165.6

Balance Sheet

Abridged

Understanding Balance Sheet

Nectar Lifesciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	1,050	1,151	1,237	1,369	1,464	1,496	1,661	1,669	1,615	1,239	1,355	1,231	1,284	1,238	253
Long-Term Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
Property Plant & Equipment - Net	1,008	1,052	1,070	900	937	926	906	885	861	832	765	690	656	633	103
Total Non-Current Assets	1,071	1,123	1,157	1,061	1,092	1,085	1,063	1,036	1,018	1,149	1,036	958	907	810	369
Total Assets	2,121	2,274	2,394	2,430	2,556	2,581	2,724	2,705	2,633	2,388	2,391	2,189	2,191	2,047	622
Total Current Liabilities	904	1,045	1,126	1,156	1,240	1,279	1,309	1,300	1,248	1,187	1,004	891	973	1,022	26
Long Term Debt	364	261	223	266	245	164	220	166	121	128	291	226	140	60	0
Total Non-Current Liabilities	432	362	341	371	362	296	356	300	249	139	299	234	149	70	13
Total Liabilities	1,336	1,406	1,467	1,528	1,602	1,574	1,665	1,600	1,497	1,326	1,303	1,125	1,122	1,091	39
Total Shareholders' Equity	784	868	927	902	954	1,007	1,059	1,105	1,136	1,062	1,088	1,065	1,069	956	582
Total Equity	784	868	927	902	954	1,007	1,059	1,105	1,136	1,062	1,088	1,065	1,069	956	582
Total Liabilities & Equity	2,121	2,274	2,394	2,430	2,556	2,581	2,724	2,705	2,633	2,388	2,391	2,189	2,191	2,047	622

Cash Flow

Abridged

Understanding Cash Flow Statement

Nectar Lifesciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	139	193	145	158	113	108	116	110	91	-47	83	-22	81	-96	-584
Working Capital - Increase/(Decrease)	-64	68	-16	-119	-62	-20	-161	-13	70	-41	-65	78	69	192	206
Net CF from Operating Activities	75	261	129	39	51	88	-45	97	162	-88	18	56	150	96	-378
Capital Expenditures - Net	251	120	102	80	82	25	33	36	36	31	-15	-50	29	44	-8
Net CF from Investing Activities	-246	-115	-102	-79	-83	-25	-35	-32	-36	-31	15	50	-29	-43	1,201
Dividends Paid - Cash - Total	2	2	2	2	3	3	1	1	1	1	1	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	167	-164	-21	66	37	-84	77	-52	-125	125	-40	-106	-118	-54	-582
Net Cash Flow from Financing Activities	165	-166	-23	64	35	-87	76	-53	-126	124	-41	-106	-118	-54	-730
Free Cash Flow to Equity	-9	-23	6	25	6	-21	-1	10	1	6	-7	0	2	-1	-952
Free Operating CF net dividend	-186	139	25	-44	-34	32	-79	58	106	-120	-8	26	121	53	-390
Free Operating CF	-184	141	27	-42	-31	35	-78	59	107	-119	-7	26	121	53	-390

Business Segment Analysis

FY End:

Mar 26

Nectar Lifesciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 12.27 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 2.01 Cr

Assets

Pharmaceuticals (100.0%)₹ 621.61 Cr

Operating Income

Pharmaceuticals (100.0%)₹ -6.78 Cr

Regional Segment Analysis

FY End:

Mar 17

Nectar Lifesciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (56.1%)₹ 979.15 CrOutside India. (43.9%)₹ 764.84 Cr

Historical Segment Analysis

Track how Nectar Lifesciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Pharmaceuticals	55	31	25	30	29	44	12

Frequently Asked Questions

What is the revenue of Nectar Lifesciences Ltd.?

The latest trailing twelve month revenue of Nectar Lifesciences Ltd. is ₹ 6.15 Cr, reflecting a 1-year growth of -99.61% and a 3-year CAGR of -84.04%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Nectar Lifesciences Ltd.?

The latest trailing twelve month net profit (PAT) of Nectar Lifesciences Ltd. is ₹ -245.06 Cr, with a 3-year earnings CAGR of -131.63%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Nectar Lifesciences Ltd.?

The trailing twelve month EBITDA of Nectar Lifesciences Ltd. is approximately ₹ -87.22 Cr (based on an operating margin of -1,417.47%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Nectar Lifesciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Nectar Lifesciences Ltd. is 0.36. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Nectar Lifesciences Ltd.?

The debt-to-equity ratio of Nectar Lifesciences Ltd. stands at 0.00. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Nectar Lifesciences Ltd.?

The estimated book value per share of Nectar Lifesciences Ltd. is 29.97 (derived from a P/B ratio of 0.34 and market price of ₹ 10.34), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Nectar Lifesciences Ltd.?

The trailing twelve month operating cash flow of Nectar Lifesciences Ltd. is ₹ 323.22 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Nectar Lifesciences Ltd. report consolidated or standalone financials?

Nectar Lifesciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.